The Effect of Magnesium Supplementation on Vascular Calcification in CKD: A Randomized Clinical Trial (MAGiCAL-CKD).

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

To investigate whether oral magnesium supplementation would slow the progression of vascular calcification in CKD, the researchers conducted a randomized, double-blinded, placebo-controlled, parallel-group, clinical trial.

Who Took Part

The abstract describes 148 subjects taking part.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and parallel-group study.

The subjects were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

Some subjects received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

The Vitamin D, K2, Magnesium and Zinc group and the comparison group ran side by side rather than switching.

What Was Measured

PubMed files the paper under topics including Magnesium, Vascular Calcification, Coronary Artery Disease, Renal Insufficiency, Chronic and Dietary Supplements.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 148 subjects.

The abstract goes on to report its results in about 13 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (Journal of the American Society of Nephrology : JASN), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.